The PennZone

  • Home
  • Books
  • Entertainment
  • Marketing
  • Non-profit
  • Music
  • Education
  • Legal
  • Business

TCB Capital Advisors Congratulates Altoida & Gregor Diagnostics on 2024 Merit Awards Recognition
The PennZone/10286921

Trending...
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • Garage door installation or repair in Minnesota? Which makes more sense for your family?
  • Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
THE WOODLANDS, Texas - PennZone -- TCB Capital Advisors proudly announces two of its partners, Altoida Inc. and Gregor Diagnostics Inc., have been recognized by the 2024 Merit Awards for Healthcare. These awards celebrate companies demonstrating groundbreaking advancements in medical technology, healthcare innovation, and patient care.

Altoida received the Gold Award for "Best Use of Artificial Intelligence," a testament to its leadership in digital health and AI applications that enhance the early detection of neurodegenerative diseases, including Alzheimer's. Altoida's pioneering NeuroMarker Platform utilizes a tablet-based application powered by augmented reality (AR) and artificial intelligence/machine learning (AI/ML) designed to deliver rapid and objective multi-modal assessment of cognitive health and function. The platform aim's to equip frontline clinicians with clinical insights to enable earlier detection, personalized care and to lead to improved patient outcomes.

Gregor Diagnostics earned the Bronze Award in the "Innovations" category, underscoring the company's achievements in developing revolutionary diagnostic solutions. Gregor Diagnostics is dedicated to pioneering advancements in prostate cancer detection, aiming to deliver earlier and more precise diagnostics for better patient outcomes.

"It's truly an honor to see Altoida and Gregor Diagnostics acknowledged for their groundbreaking work," Sam Libby, President and Managing Director at TCB Capital Advisors, expressed. "The Merit Awards spotlight innovators who are reshaping the future of healthcare, and we at TCB are so proud to support such visionary leaders who are driving remarkable advancements in patient care and medical science."

More on The PennZone
  • Put Your Herd on Your Phone: Kiko Nation Makes Livestock Management Simple
  • Future Intelligence Think Tank Surpasses 1,000 Members Exploring Human and Artificial Intelligence
  • Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
  • Headline: House of Nova Paints Every Face in Gold at New York Fashion Week
  • Can Government Operate Better Through Innovation?

The 2024 Merit Awards for Healthcare highlights outstanding achievements across various healthcare sectors, selecting winners based on their significant impact on improving healthcare delivery and innovation.

For more information please visit Altoida and Gregor Diagnostics. To learn more about TCB Capital Advisors, visit TCB Capital Advisors.

About Altoida
Altoida is the leader in developing digital biomarkers for neurological conditions, including Alzheimer's disease. Its innovative Altoida Digital NeuroMarker Platform leverages artificial intelligence and augmented reality (AR) to deliver objective and precise assessments of cognitive health. The platform uses a tablet-based app that offers a quick, self-administered series of motor, speech, and AR tasks, simulating daily activities to evaluate brain health. These tasks measure key cognitive metrics, including micro-movements, processing speed, reaction time, and spatial navigation. Altoida is a privately held, venture-backed diagnostics company with a proprietary platform built on over 20 years of scientific research. Its evidence-based technology has been featured in numerous global pharmaceutical studies and published in prestigious peer-reviewed journals, including Nature Digital Medicine.

About Gregor Diagnostics
Gregor Diagnostics Inc. is a molecular diagnostics company developing groundbreaking diagnostics for prostate cancer. Gregor Diagnostics' patient-friendly test is sensitive enough to detect prostate cancer at the earliest stages of the disease and differentiate between indolent and aggressive cancer upon detection. Gregor Diagnostics is making early detection and less invasive identification and management of prostate cancer a reality while decreasing the overdiagnosis and overtreatment of indolent prostate cancer.

More on The PennZone
  • Michael H. Kaplan Advocates for Seriously Injured Colorado Workers Who Need In-Home Care
  • Her Song Lives On: Remembering Mrs. Darlene Davis Porter
  • Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
  • Pittsburgh Creators Launch Clever New Children's Book, "The Sock Sleuth!"
  • Canadian Tint Expo 2027: Why Every Window Tinter Should Compete in Niagara Falls on April 3rd & 4th

About TCB Capital Advisors

TCB Capital Advisors is a boutique investment bank and advisory firm focused on the healthcare and life sciences sectors. The firm specializes in advising clients with their buying, selling, investment, and growth strategies, leveraging decades of combined Wall Street and industry experience. TCB Capital Advisors offers a tailored approach, focusing on transaction advisory, corporate development, revenue growth, and post-transaction integration, working with clients across venture, growth, and middle-market verticals. Founded in 2023 by former members of the healthcare team at Piper Sandler, TCB Capital Advisors is headquartered in Houston, TX with offices/team members based in New York, North Carolina, and Tennessee. Securities are offered through Finalis Securities, LLC (member FINRA/SIPC). TCB Capital Advisors is not a registered broker-dealer, and Finalis Securities, LLC and TCB Capital Advisors are separated, unaffiliated entities. For more information, please visit www.tcbcapitaladvisors.com.

Contact
Melinda Jackson Public Relations
***@melindajacksonpr.com


Source: TCB Capital Advisors

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Houston This October
  • The Social Capital Revolution Comes to Phoenix!
  • Lawsuit Alleges American Deli Food Caused Severe Illness, Acute Kidney Failure, And Eight-day Hospitalization
  • FBI/DoW plot uncovered to hurt Trump/Vance through encouraged "widespread" cybersecurity breaches and racketeering theft of $80m in USDA payments
  • Bettingbladet releases H1 2026 report on the Swedish online gambling market
  • Garage door installation or repair in Minnesota? Which makes more sense for your family?
  • SMACK Fight Week Takes Over Philadelphia
  • Super Rooter Expands to 190 Plumbing, Sewer, and Drain Service Locations Across the United States
  • European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP
  • VICTURY Sports Announces Formation of Youth Sports League Built on the Official, Patented, and Award-Winning Keepy Uppy® Ball
  • Spearmint Publishes Full Design of Its Mining Pool Before Building It, Including Legal Drafts
  • Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran
  • Cress Creeks Farm Opens Fall Corn Maze and Baby Lamb Hayride Experience in Ellijay, Georgia
  • Brewtay Coffee Introduces Specialty Instant Line Designed for High-Velocity Commuters and Travelers
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • Ten Ten Ten Awards Provisional Certification to Cara AI for Home-Based Health Assessments
  • IDI Consulting Partners with the American Heart Association to Advance Heart Health Awareness
  • Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
  • Bethany Nikitenko Appointed to Philadelphia Trial Lawyers Association Diversity Committee
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)

Popular on PennZone

  • Benny Turner Revisits Freddie King's Legacy for 50th Anniversary of His Passing - 221
  • Easwe Lightweight Electric Wheelchair Collection with Travel-Focused Mobility Solutions - 196
  • Church Tradition Takes an Unexpected Turn at the Ford Community & Performing Arts Center - 189
  • Master Of Science, Juggernaut Of The Screen: Landon Brittain Emerges As Hollywood's Most Unlikely Leading Man - 182
  • 3ptechies Partners with Coolmuster to Give Away Data Recovery Software Licenses - 174
  • Black Dog Venture Partners and VC Fast Pitch to Host "San Francisco Investors and Innovators" Networking Event - 154
  • FindCostSeg Launches Nationwide Directory for Cost Segregation Providers - 147
  • GitKraken Names Jim Shaw CEO as Software Teams Move From AI Adoption to Multi-Agent Orchestration - 144
  • INAD Warriors' 4th Annual "Dancing with the INAD Stars" Gala - 141
  • Michael Fischer, President and CEO of Client 1st Financial, Named to LVB 300 - 120

Similar on PennZone

  • Ragin' Cajun Announces New Cheeseburger Seasoning on National Cheeseburger Day
  • Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
  • Future Intelligence Think Tank Surpasses 1,000 Members Exploring Human and Artificial Intelligence
  • Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
  • Can Government Operate Better Through Innovation?
  • Michael H. Kaplan Advocates for Seriously Injured Colorado Workers Who Need In-Home Care
  • Infinity Infusion Solutions Named Finalist for D Magazine's D CEO 2026 Excellence in Healthcare Awards
  • Building a Diversified Healthcare Platform as Exosome Science, Telehealth, Diagnostics & Strategic Acquisitions Converge: NexTel Medical (OTCID: MAJI)
  • International Society of Medical AI Convenes Global Faculty in Florence for ISMAI 2026
  • Retell AI White Label Platform for Agencies Launched by VoiceAIWrapper, With Branded Client Portals and No Per-Minute Markup
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us